Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633011 | 0.88 | SIGMAR1 (0.52) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL633009 | 0.88 | SIGMAR1 (0.52) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL1223231 | 0.84 | SIGMAR1 (0.55) | SIGMAR1KMT2AGRK2CTDSP1 | |
| SCHEMBL1223237 | 0.84 | SIGMAR1 (0.55) | SIGMAR1KMT2AGRK2CTDSP1 | |
| SCHEMBL591159 | 0.84 | MAOA (0.59) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL591514 | 0.84 | MAOA (0.59) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL591161 | 0.84 | MAOA (0.59) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL1712582 | 0.81 | GRK2 (0.49) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL2294706 | 0.81 | GRK2 (0.49) | SIGMAR1KMT2AGRK2CTDSP1POLB | |
| SCHEMBL632626 | 0.81 | KMT2A (0.48) | SIGMAR1KMT2AGRK2CTDSP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
| EP-2245028-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | SIGMAR1 28/4885KMT2A 1674/4885GRK2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.